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Abstract The natriuretic peptide (NP) system, which in-
cludes atrial natriuretic peptide, B-type natriuretic peptide,
and C-type natriuretic peptide, has an important role in car-
diovascular homeostasis, promoting a number of physiologi-
cal effects including diuresis, vasodilation, and inhibition of
the renin-angiotensin-aldosterone system. Heart failure (HF)
is associated with defects in NP processing and synthesis, and
there is a strong relationship between NP levels and disease
state. NPs are useful biomarkers in HF, and their use in diag-
nosis and evaluation of prognosis is well established, particu-
larly in patients with HF with reduced ejection fraction
(HFrEF). There has also been interest in their use to guide
disease management and therapeutic decision making. An un-
derstanding of NPs in HF has also resulted in interest in syn-
thetic NPs for the treatment of HF and in treatments that target
neprilysin, a protease that degrades NPs. A novel drug, the
angiotensin receptor neprilysin inhibitor sacubitril/valsartan
(LCZ696), which simultaneously inhibits neprilysin and
blocks the angiotensin II type I receptor, was shown to have
a favorable efficacy and safety profile in patients with HFrEF
and has been approved for use in such patients in Europe and
the USA. In light of the development of treatments that target
neprilysin and of recent data in relation to synthetic NPs, it is
timely to review the current understanding of the role of NPs
in HF and their use in diagnosis, evaluating prognosis and
guiding treatment, as well as their place in HF therapy.
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Introduction
Heart failure (HF) is a complex clinical syndrome, character-
ized by progressive left ventricular (LV) dysfunction and im-
paired hemodynamics [1]. HF is associated with significant
morbidity and mortality [2, 3], and novel therapies are re-
quired to improve patient outcomes.
The pathophysiology of HF is complex, involving activa-
tion of the sympathetic nervous system (SNS) and the renin-
angiotensin-aldosterone system (RAAS) to maintain cardiac
output and organ perfusion; however, sustained activation of
these neurohormonal systems can be detrimental [1].
Natriuretic peptides (NPs) are a family of structurally relat-
ed peptides, including atrial natriuretic peptide (ANP), B-type
natriuretic peptide (BNP), and C-type natriuretic peptide
(CNP) [4]. They are secreted in response to increased cardiac
wall stress (Fig. 1a [5–14]) to oppose the actions of the RAAS
and SNS [4]. NPs mediate physiological effects including di-
uresis, natriuresis, vasodilation, and RAAS inhibition via na-
triuretic peptide receptors (NPRs) [15] and can be degraded
via secretion into bodily fluids [16], through NPR-C [15] or
via the protease neprilysin (which has a higher affinity for
ANP and CNP than BNP (Fig. 1b) and does not degrade N-
terminal [NT-]proBNP or NT-proANP) [7, 9].
Of note, defective NP processing and synthesis and resis-
tance to bioactive NPs have been observed in HF [7, 10, 17].
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In this review, we will discuss the role of the NP system
in the management of HF, including the diagnostic and
prognostic value of NPs, the utility of NPs in guiding
therapy, and the enhancement of the NP system as a thera-
peutic strategy. Moreover, we will provide recommendations
regarding the integration of NP measurement into HF
management.
What is the value of natriuretic peptides
as biomarkers in patients with HF?
BNP/NT-proBNP for diagnosis and prognosis
In patients with suspected HF, guidelines recommend BNP/
NT-proBNP testing to confirm or exclude a diagnosis of HF
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Fig. 1 Synthesis and processing of NPs via neprilysin in patients with
HF [5,6,7,8,9,10,11,12,13,14]. a ANP is synthesized in atrial
cardiomyocytes as pre-proANP; the sP of which is cleaved to form
proANP. Upon secretion, proANP is processed by membrane-bound
and soluble corin, generating an N-terminal peptide (NT-proANP; 98
amino acids), and an active C-terminal peptide (ANP; 28 amino acids).
In patients with HF, corin levels are decreased, resulting in an increase in
predominantly unprocessed ANP. BNP is synthesized as pre-proBNP in
ventricular cardiomyocytes. Removal of a sP from pre-proBNP forms
proBNP, which is processed by membrane-bound and soluble furin, and
corin, to release the N-terminal portion (NT-proBNP; 76 amino acids),
and the biologically active C-terminal (BNP; 32 amino acids). CNP is
widely expressed in the vasculature and found in high concentrations in
the endothelium. CNP expression has also been reported in
cardiomyocytes at gene and protein levels. CNP is synthesized as pre-
proCNP; the sP of which is cleaved to form proCNP. Processing of
proCNP (103 amino acids) may occur via furin to yield a53 amino acid
C-terminal peptide (CNP-53), the major active form of CNP in the
tissues. In the systemic circulation, a 22 amino acid form of CNP
dominates (CNP-22), but the protease responsible for this cleavage is
unknown. b Cellular and circulating soluble neprilysin are major
contributors to ANP degradation. In contrast, BNP is a poor neprilysin
substrate. Thus, neprilysin inhibition (e.g., via sacubitril) is most likely
associated with greater augmentation of ANP activity than BNP activity.
Neprilysin also has a high affinity for CNP, and as such, inhibition of
neprilysin is expected to increase levels of CNP. ANP atrial natriuretic
peptide, BNP B-type natriuretic peptide, CNP C-type natriuretic peptide,
HF heart failure, NP natriuretic peptide, NT-proANPN-terminal proANP,
NT-proBNP N-terminal proBNP, Nt-proCNP N-terminal proCNP, sP
signal peptide, TGF transforming growth factor. Adapted with
permission from Triposkiadis F et al. Global left atrial failure in heart
failure. Eur J Heart Fail 2016;18:1307–20. © 2016 The Authors.
European Journal of Heart Failure © 2016 European Society of
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[18, 19]. Levels of BNP and NT-proBNP are significantly
elevated in patients with HF and increase with the severity
of disease [20, 21], but are also influenced by left
ventricular ejection fraction (LVEF), age, sex, renal
function, sodium levels, and body mass index (BMI), as
well as genetic factors and comorbidities [20, 21]. As
such, the util i ty of BNP and NT-proBNP, while
established in the diagnosis and determination of progno-
sis of patients with HF with reduced ejection fraction
(HFrEF), may be limited in patients with HF with pre-
served ejection fraction (HFpEF) [22, 23]. For instance,
levels of BNP and NT-proBNP are influenced by comor-
bidities that are frequently associated with HFpEF, with
atrial fibrillation and renal disease resulting in increased
levels, and obesity leading to decreased levels of these
NPs [22, 24]. In addition, while BNP and NT-proBNP
levels are typically lower in patients with HFpEF com-
pared with patients with HFrEF, levels of BNP have also
been reported within the normal range for patients with a
preserved LVEF (in this study, diagnosis of HFpEF was
based on previously published criteria, requiring a LVEF
>50% and a left ventricular end-diastolic volume index
<97 ml/m2, and was confirmed by physical exam, echo-
cardiography, and invasive hemodynamic testing) [22, 25,
26]. These factors should be taken into consideration
when interpreting NP levels in patients with suspected
HFpEF.
Elevated levels of BNP and NT-proBNP are also
associated with worse prognosis in terms of mortality
and hospital readmission in patients with HFrEF and
HFpEF, with a similar prognosis observed among patients
for given values of BNP and NT-proBNP, regardless of
ejection fraction [20, 22, 26, 27]. In addition, NT-proBNP
values on admission for acute HF (AHF) and at discharge
are predictive of all-cause mortality [28], while decreases
in NT-proBNP levels during hospitalization are associated
with reduced cardiovascular (CV) mortality, HF readmission
[28], and all-cause mortality [29]. High and increasing
NT-proBNP values have also been associated with poor
outcomes [30].
BNP/NT-proBNP levels to guide HF treatment
A BNP/NT-proBNP-guided strategy is of interest due to
the underutilization of evidence-based therapies and the
poor outcomes observed with current management strate-
gies in patients with HF [31]. However, trials guided by
BNP/NT-proBNP in patients with HF have generally been
small and heterogeneous in design and have reported con-
flicting results [32]. In addition, patients with HFpEF
have only been included in one of these trials (TIME-
CHF; Trial of Intensified versus Standard Medical
Therapy in Elderly Patients with Congestive Heart
Failure) [22]. Thus, further studies are needed to clarify
the potential clinical benefit of BNP/NT-proBNP-guided
treatment, as well as the possible interactions with age
and comorbidities [21, 33], impact on quality of life, safe-
ty and cost-effectiveness, and appropriate target cutoff
values for NT-proBNP and BNP [31, 33].
Despite the above limitations, the overall impression is
that BNP/NT-proBNP-guided treatment may be useful,
and this is reflected in the current American College of
Cardiology Foundation (ACCF)/American Heart
Association (AHA) HF guidelines, which are in favor of
the use of NPs to guide evidence-based treatment [19]. A
prospective study (Guiding Evidence Based Therapy
Using Biomarker Intensified Treatment, GUIDE-IT) to
determine the impact of NT-proBNP-guided therapy on
time to CV death or HF hospitalization at 12 months in
∼1100 patients with HFrEF when compared with usual
care was recently terminated due to futility, with no
difference in the primary outcome observed between
treatment groups [34–36]. Despite this, the results are
expected to provide further insight into the usefulness of
biomarker-guided therapy in HF.
BNP or NT-proBNP?
While BNP and NT-proBNP are both gold standard bio-
markers for diagnosis and evaluation of prognosis in patients
with HF [18, 19], NT-proBNP may be superior to BNP for the
detection and evaluation of HF and the prediction of outcome
[33, 37]. For instance, in the valsartan in heart failure trial,
both NT-proBNP and BNP concentrations predicted all-
cause mortality (hazard ratios [HRs] 2.07 and 1.87, respec-
tively), mortality and morbidity (HRs 2.20 and 2.05, respec-
tively), and hospitalization for HF (HRs 2.66 and 2.48, respec-
tively) [37]. However, NT-proBNP, compared with BNP, pro-
vided significantly greater predictive value for mortality and
morbidity (p = 0.0332) and hospitalization for HF
(p = 0.0143), as well as marginally higher predictive value
for all-cause mortality (p = 0.0734) when values were com-
pared by ROC curves [37]. With a longer half-life and there-
fore greater circulating concentration and lower intrinsic bio-
logical variability compared with BNP [38], NT-proBNP may
be a more accurate marker of ventricular stress and, conse-
quently, determinant of prognosis in patients with HF [33]. In
addition, as NT-proBNP is not degraded by neprilysin, it rep-
resents a useful biomarker for the management of patients
with HF who receive therapies that inhibit this enzyme [7].
ANP/MR-proANP for diagnosis and prognosis
In patients with HF, levels of ANP increase to a lesser
extent than those of BNP (10–30-fold vs. 200–300-fold,
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respectively, compared with control subjects) and ANP is
thought to be secreted later than BNP/NT-proBNP in re-
sponse to myocardial stress [39]. The use of mid-regional
proANP (MR-proANP, a more stable form of NT-
proANP) in the diagnosis of AHF has been evaluated.
The performance of MR-proANP in the diagnosis of
AHF was slightly lower than that of proBNP, BNP, and
NT-proBNP in one study [40] but, in another report, dem-
onstrated non-inferiority to BNP and improved diagnostic
accuracy in the BNP Bgray zone^ (BNP levels 100–
500 pg/mL) and in patients with obesity [41]. In addition,
MR-proANP was an independent predictor of HF diagno-
sis in a model that included NT-proBNP [42]. These re-
sults suggest that combined use of MR-proANP and either
BNP or NT-proBNP may provide superior diagnostic ac-
curacy than either NP alone. The current European
Society of Cardiology (ESC) guidelines recommend mea-
suring levels of BNP, NT-proBNP, or MR-proANP to ex-
clude noncardiac causes of acute dyspnea in patients with
suspected AHF [18, 19].
When interpreting ANP values in the clinic, it is
important to consider them as a direct indicator of atrial
size [43]. Dilated atria reflect chronicity of increased
filling pressure and are a strong predictor of long-term
mortality. For instance, in patients with AHF, MR-
proANP had the greatest prognostic value versus BNP
and NT-proBNP at 5 years [40]. In addition, MR-
proANP is a strong predictor of subsequent outcome in
patients with chronic HF (CHF) [44] and was the
strongest predictor of CV outcome in patients with CHF
followed over 15 years compared with all other considered
markers [45]. Thus, MR-proANP appears to perform well in
both AHF and CHF. However, as available studies are limited,
the true utility of this NP for the diagnosis and prognosis of
patients with HF is unknown. It is also unknown if
MR-proANP may aid in guiding the management of patients
with HF, as has been shown for BNP.
CNP for diagnosis and prognosis
The role of CNP in HF has not been established. In
members of the general population, CNP was reported to
circulate at various concentrations, was unaffected by sex,
and was weakly associated with age, but elevated levels
identified a high-risk phenotype that included CV
comorbidities and LV dysfunction [46]. In hospitalized
patients with HF, NT-proCNP was a strong predictor of
all-cause mortality and HF hospitalization at 18 months in
patients with HFpEF, but not in those with HFrEF [47].
CNP has also emerged as a biomarker of structural and
functional renal impairment in HF and chronic renal
disease states [48].
What strategies have been investigated to enhance
the NP system for the treatment of HF?
Based on an increased understanding of the role of the NP
system in HF, several therapeutic strategies to enhance the
levels of NPs have been investigated. These include the
administration of synthetic NPs and the inhibition of
neprilysin.
Therapeutic potential of NPs
Synthetic forms of NPs have been investigated in the
treatment of HF, with some peptides being approved in
specific countries for the treatment of patients with AHF
[49].
Synthetic ANPs include anaritide and carperitide.
Carperitide was approved in Japan for the treatment of
patients with AHF in 1995, although there is limited
evidence to support this indication [49, 50].
Nesiritide, a synthetic BNP, was approved for the treat-
ment of AHF in the USA in 2001 and has been observed
to improve hemodynamic parameters in patients with
HFrEF [49, 50]. However, in the Acute Study of
Clinical Effectiveness of Nesiritide in Decompensated
Heart Failure trial including patients hospitalized with
AHF (N = 7141), nesiritide treatment did not improve
rates of rehospitalization for HF or all-cause mortality at
30 days (coprimary endpoint), had a small, nonsignificant
effect on dyspnea (coprimary endpoint) and increased the
rates of hypotension, compared with placebo [51]. As a
result, nesiritide is not recommended for routine use in the
broad population of patients with AHF [51].
Ularitide is a synthetic form of the NP urodilatin,
which is secreted by the kidney. Previous studies have
suggested that ularitide may have a role in the treatment
of patients with AHF. In the recently completed Trial of
Ularitides’s Efficacy and Safety in Patients with Acute
Heart Failure in patients with AHF (N = 2157), ularitide
treatment was associated with fewer in-hospital worsening
HF events, compared with placebo [52]. No difference
between treatment groups was observed for either of the
two primary endpoints of CV mortality at 15 months and
distribution of the hierarchical clinical composite (which
characterized patients according to changes in symptoms
and the occurrence of worsening HF or death within 48 h)
[52, 53]. In addition, ularitide treatment did not result in
improvement in the 30-day readmissions for HF, or in
death from any cause or CV hospitalization at 6 months
[52].
Finally, a chimeric peptide known as cenderitide,
which consists of portions of CNP and Dendroaspis NP
(a NP isolated from the venom of the eastern green
mamba snake), may have beneficial renal effects, as
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observed in animal models [54]. Further studies are need-
ed to investigate the potential utility of this peptide in the
treatment of patients with HF, and a number of clinical
studies are ongoing [54].
Neprilysin inhibition as a therapeutic strategy
As mentioned above, defective NP synthesis/processing
and NP resistance may occur in HF. In patients with HF,
high concentrations of circulating soluble neprilysin have
been reported and have been significantly associated with
CV death, HF hospitalization, and all-cause death [5]. It
should be noted that in this study, the total protein con-
centration of neprilysin, and not the enzymatic activity,
was assessed [5]. In theory, the inhibition of neprilysin
would increase the levels of bioactive forms of NPs and,
therefore, enhance their beneficial effects (Fig. 2) [55,
56]. However, neprilysin has a number of physiological
substrates, including angiotensin I and II, in addition to
NPs [7]. Inhibition of neprilysin to enhance the beneficial
effects of the NP system may also result in an increase in
angiotensin II, which counteracts any potential benefit [7].
Indeed, stand-alone neprilysin inhibitors have not demon-
strated efficacy beyond that of current pharmacotherapies
[4]. The inhibition of neprilysin should therefore be com-
bined with simultaneous suppression of the RAAS [7].
Combined inhibition of neprilysin, aminopeptidase
(APP), and angiotensin-converting enzyme (ACE) via
omapatrilat demonstrated trends towards greater efficacy
when compared with enalapril [57]. However, further
development of these agents was stopped due to safety
concerns, primarily due to increased incidence of
angioedema [4, 57]. The increased risk of angioedema
with omapatrilat was thought to be due to the simulta-
neous inhibition of neprilysin, ACE, and APP involved
in the breakdown of bradykinin, a vasoactive peptide that
in turn is implicated in the pathogenesis of angioedema
[7].
Sacubitril/valsartan (also known as LCZ696), an
angiotensin receptor neprilysin inhibitor (ARNI), which
consists of the molecular components of valsartan (an
angiotensin receptor blocker, ARB) and the neprilysin
inhibitor prodrug AHU377 (sacubitril), provides simulta-
neous inhibition of neprilysin and blockade of the
angiotensin II type 1 (AT1) receptor (and thus, inhibition
of the RAAS) [7, 58]. Sacubitril/valsartan was designed in
such a way to minimize the risk of angioedema, as it only
inhibits one enzyme (neprilysin) involved in the metabolism
of bradykinin, with no effect on ACE [7].
Recent data indicate that the treatment approach repre-
sented by sacubitril/valsartan is beneficial. In the prospec-
tive comparison of ARNI with angiotensin-converting en-
zyme inhibitor (ACEI) to Determine Impact on Global
Mortality and morbidity in Heart Failure (PARADIGM-
HF) trial in patients with HFrEF (n = 8442), sacubitril/
valsartan demonstrated superior efficacy when compared
with ACEI enalapril on CV mortality and HF hospitaliza-
tion, all-cause mortality, and quality of life as assessed by
the Kansas City Cardiomyopathy Questionnaire over a
mean follow-up of 27 months [59]. Treatment with
sacubitril/valsartan was not accompanied by important
safety concerns [59]. As such, sacubitril/valsartan was ap-
proved for the treatment of patients with HFrEF in Europe
and the USA. The current ESC-HF guidelines recommend
sacubitril/valsartan to replace ACEI/ARB in ambulatory
patients with HFrEF who remain symptomatic despite
treatment with an ACEI, beta-blocker, and MRA [18],
while an ACCF/AHA guideline update recommends the
use of sacubitril/valsartan in patients with chronic symp-
tomatic HFrEF New York Heart Association class II or III
who can tolerate an ACEI or ARB [60].
Sacubitril/valsartan treatment resulted in significant in-
creases in levels of urinary cyclic guanosine monophosphate
(cGMP) and BNP (Fig. 2a) compared with enalapril,
reflecting inhibition of neprilysin via sacubitril and the subse-
quent enhancement of NP levels (via the activation of intra-
cellular cGMP) [55]. In contrast, patients treated with
sacubitril/valsartan had significantly reduced levels of NT-
proBNP at 4 weeks and 8 months when compared with pa-
tients treated with enalapril, indicating reduced cardiac wall
stress (Fig. 2b) [55]. A greater number of patients treated with
sacubitril/valsartan attained an NT-proBNP level <1000 pg/
mL when compared with enalapril [61]. An NT-proBNP level
<1000 pg/mL at 1 month resulted in a 59% reduction in risk of
CV death or HF hospitalization when compared with patients
whose NT-proBNP levels did not decrease to <1000 pg/mL at
1 month [61]. Similarly, in the Prospective Comparison of
ARNI with ARB on Management of Heart Failure with
Preserved Ejection Fraction (PARAMOUNT-HF) trial in pa-
tients with HFpEF (n = 301), levels of NT-proBNP were sig-
nificantly reduced 12 weeks following the initiation of treat-
ment in patients who received sacubitril/valsartan compared
with patients who received valsartan [56].
As NT-proBNP is not metabolized by neprilysin [7], assess-
ment of this biomarker may accurately reflect the changes in
myocardial wall stress following treatment with an ARNI [9]
and, thus, aid prognosis, risk stratification, and, potentially,
guidance of disease management and treatment strategy in pa-
tients with HF throughout the patient journey. This may be of
particular importance in patients who appear clinically stable,
but in whom disease progression, driven by neurohormonal
imbalance, is ongoing despite pharmacological treatment.
The role of MR-proANP in patients with HF receiving
sacubitril/valsartan therapy is currently unknown. The precur-
sor form of ANP is not a substrate of neprilysin, and changes
should mostly reflect reduced atrial filling pressure and
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myocardial stress during neprilysin inhibition and AT1 recep-
tor blockade. Thus, plasma MR-proANP could be a valid
alternative to NT-proBNP assessment. Future studies should
assess the role of MR-proANP during neprilysin inhibition.
How can the measurement of NPs be integrated
into clinical practice to guide management?
NPs remain the gold standard for establishing the diagnosis
and prognosis of patients with AHF and CHF. In acute cardiac
care, NPs are used in a diagnostic setting to rapidly rule out
AHF in patients evaluated for acute dyspnea. With cutoff
values of 100 ng/L (BNP), 300 ng/L (NT-proBNP), and
120 pmol/L (MR-proANP), NPs have high negative predic-
tive values (90–98%), but less robust positive predictive
values (56–67%) [12] (although it should be noted that cutoff
thresholds will vary according to the chosen assay and conse-
quently, NP values obtained via different assays cannot be
compared) [62, 63]. Moreover, NP levels may be used for
disease management and treatment guidance in hospitalized
patients with HF, as decreases >30% versus baseline are asso-
ciated with favorable post-discharge outcomes [64].
As already discussed, several factors need to be taken into
account for correct interpretation of NP levels in HF, such as
age, sex, BMI, renal function, cardiac function, comorbidities,
and ongoing therapies. In the latter regard, the introduction of
an ARNI for the treatment of patients with HF adds a further
variable. Clinicians need to know how to evaluate the clinical
meaning of NP levels in patients receiving an ARNI to im-
prove disease management. Changes in NP levels should rep-
resent the result of both the intrinsic mechanism of ARNI
action and the consequent improvement of cardiac function,
not excluding the impact of the abovementioned anthropomet-
ric and renal function parameters.
The interpretation of BNP testing in patients with acute
dyspnea will depend on whether or not patients have received
sacubitril/valsartan, although the relative increases in plasma
BNP concentrations in patients treated with sacubitril/
valsartan in the PARADIGM-HF trial were modest (from a
median of approximately 200 ng/L at baseline to approximate-
ly 225 ng/L at 8 months) [12, 55]. It is unlikely that the diag-
nostic utility of BNP testing would be impaired in patients
with acute dyspnea who have not been receiving sacubitril/
valsartan, but using BNP levels for the guidance of treatment
in patients with CHF receiving sacubitril/valsartan may not be
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Fig. 2 Changes in plasma levels of BNP (a) and NT-proBNP (b) follow-
ing treatment with sacubitril/valsartan compared with enalapril in the
PARADIGM-HF trial [55, 56]. p values denote significant differences
between the two treatment groups. All patients received enalapril, follow-
ed by sacubitril/valsartan, during the single-blind run-in period. Groups
represented here show division by final randomization group. ACEI
angiotensin-converting-enzyme inhibitor, ARNI angiotensin receptor
neprilysin inhibitor, BNP B-type natriuretic peptide, ENL end of the enal-
april phase of the run-in period, LCZ end of the sacubitril/valsartan phase
of the run-in period, NT-proBNP N-terminal pro B-type natriuretic pep-
tide, PARADIGM-HF Prospective comparison of ARNI with ACEI to
Determine Impact on Global Mortality and morbidity in Heart Failure
trial. Reproduced with permission of Wolters Kluwer Health, Inc.
Copyright © 2015, American Heart Association, Inc. From Packer M,
et al. Angiotensin receptor neprilysin inhibition compared with enalapril
on the risk of clinical progression in surviving patients with heart failure.
Circulation 2015;131:54–61 http://circ.ahajournals.org/content/131/1/54.
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feasible. However, as NT-proBNP is not metabolized by
neprilysin [7], the interpretation of diagnostic and prognostic
NT-proBNP testing in HF would likely be unaffected by pre-
vious sacubitril/valsartan treatment.
At the current stage, the precise behavior of ANP and MR-
proANP in response to ARNI treatment is not known [12],
and therefore, it is difficult to establish if these NPs can either
mimic or even be superior to BNP/NT-proBNP assessment in
patients with HF. ANP is expected to represent the most suit-
able marker of effective neprilysin inhibition, and experimen-
tal studies have confirmed this [58]. Higher ANP levels, de-
spite an improvement of cardiac function, documented by
both clinical and echocardiographic evaluations, should there-
fore be a hallmark of neprilysin inhibition. However, the upper
limit of ANP should be reconsidered in HF to establish the
exact level above which values are indicative of efficacious
neprilysin inhibition, rather than cardiac dysfunction. On the
other hand, changes inMR-proANP level may mimic those of
NT-proBNP, as these peptides are not substrates of neprilysin
and mostly reflect the cardiac function of treated patients. The
scenario may become even more complex when considering
that, in order to properly interpret the circulating NP levels in
patients with HF receiving ARNI treatment, the concomitant
impact of other pharmacological treatments, such as beta-
blockers, MRAs, and diuretics, should be taken into account,
as the overall efficacy of a HF treatment strategy certainly
influences circulating levels of NPs.
Finally, in addition to determining levels of NT-proBNP,
assessment of the levels of other markers that are independent
from the action of ARNI, yet reflect hemodynamic changes
and beneficial effects of ARNI on the CV system, such as
cardiac troponins and ST2, may be valuable. It is also impor-
tant to remark that both clinical and echocardiographic evalu-
ations are necessary to integrate the information obtained with
regard to NP levels, particularly in patients with symptomatic
HF.
Summary
NPs mediate beneficial physiological effects in patients with
HF, including vasorelaxation and stimulation of diuresis and
natriuresis, to alleviate neurohormonal and hemodynamic im-
balance in HF and counteract the deleterious effects of the
RAAS and SNS. Unfortunately, HF is associated with an in-
creased ratio of unprocessed/processed NPs and, eventually,
the development of NP resistance. The use of NPs in the
diagnosis and evaluation of the prognosis of patients with
HF is well established, particularly in patients with HFrEF.
Their use in guiding the therapy of patients with HF, as well
as the therapeutic potential of synthetic NPs, requires further
investigation.
Morbidity and mortality remain high in patients with HF,
and novel therapies are required. Through blockade of the
RAAS via AT1 antagonism with valsartan and inhibition of
neprilysin via sacubitril, sacubitril/valsartan has been shown
to increase the levels of ANP and BNP (most likely the proc-
essed bioactive forms) and to decrease levels of NT-proBNP,
with significant improvement in the outcomes of patients with
HFrEF observed, including decreases in rates of CV mortality
and HF hospitalization. Usually, increases in concentrations of
ANP and BNP are suggestive of increased cardiac wall stress;
however, prevention of the degradation of NPs through
neprilysin inhibition (via sacubitril/valsartan) results in phar-
macological elevations in the levels of these NPs. Conversely,
as NT-proBNP is not degraded by neprilysin, changes in the
levels of this peptide are indicative of sacubitril/valsartan-
induced changes in hemodynamic profile, with decreases in
NT-proBNP levels suggestive of reduced cardiac wall stress.
Measurement of NT-proBNP therefore provides important in-
formation to guide optimal HF management in this setting.
ANP/MR-proANP and other biomarkers may help to inter-
pret the clinical meaning of changes in BNP/NT-proBNP
levels during neprilysin inhibition and to improve biomarker-
guided disease management and, ultimately, the outcomes of
patients with HF. Further studies are required to determine the
clinical utility of these markers during neprilysin inhibition.
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